Polycyclic carbamoyl pyridone derivative as well as preparation method and pharmaceutical composition thereof
By developing polycyclic carbamoylpyridone derivatives, the problems of existing HIV integrase inhibitor resistance and lifelong medication use have been solved, and effective inhibition of HIV integrase and improvement of drug safety have been achieved.
Patent Information
- Application Number
- CN202411081363.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-11-12
- Filing Date
- 2022-11-03
- Publication Date
- 2024-11-22
AI Technical Summary
The existing HIV integrase inhibitor has a low resistance barrier, and lifelong medication brings inconvenience and side effects. It is necessary to develop new integrase inhibitors to improve drug resistance barriers and bioavailability and improve clinical toxic side effects.
Develop polycyclic carbamoylpyridone derivatives to prevent and treat HIV integase activity by selectively inhibiting HIV integase activity, and to reduce the number of administrations through excellent permeability and drug properties, improve drug compliance and safety .
Polycyclic carbamoylpyridone derivatives can effectively inhibit HIV integase, improve drug resistance barriers, reduce adverse reactions, enhance drug compliance, and provide better treatment options.
Smart Images

Figure CN118994196A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention application with an application date of November 3, 2022, application number 202211367919.5, and invention name “Polycyclic aminoformyl pyridone derivatives, preparation methods and pharmaceutical compositions thereof”. Technical Field
[0002] The present invention relates to the technical field of drugs for treating AIDS infection, and in particular to polycyclic aminoformyl pyridone derivatives, preparation methods thereof and pharmaceutical compositions. Background Art
[0003] AIDS, the full name of which is "Acquired Immune Deficiency Syndrome" (AIDS), is a highly fatal infectious disease caused by infection with the human immunodeficiency virus (HIV). HIV can specifically attack and destroy human immune cells, causing damage to the human immune system, the gradual loss of related immune functions, and gradually becoming the target of many diseases, leading to various serious opportunistic infections, tumors, etc., and eventually developing into AIDS.
[0004] HIV is a retrovirus whose genetic information is stored in ribonucleic acid (RNA). HIV selectively recognizes and invades immune cells (CD4+ lymphocytes) with CD4 molecules on their surface, and enters host cells through the interaction between its surface protein and CD4 molecules. Once inside the host cell, HIV's genetic material, single-stranded RNA, is used as a template to form complementary double-stranded DNA under the action of reverse transcriptase and enter the host cell nucleus. It is then integrated into the host cell genome after being catalyzed by integrase, and then transcribed, translated, and cleaved into new viral proteins under the action of proteases, eventually forming new mature viral particles that are released outside the cell to infect more host cells, over and over again.
[0005] Human cells do not have functional analogs of integrase, and the drug toxicity is relatively low during use, so integrase has become an ideal target for anti-HIV drugs. Integrase inhibitors mainly inhibit HIV integrase required for viral replication, preventing the HIV genome from covalently inserting or integrating into the host cell genome in the early stages of infection, thereby producing an antiviral effect. Integrase inhibitors have a significant efficacy, can quickly reduce the number of viruses and are generally well tolerated. They have been increasingly supplemented and included in the first-line treatment regimen by relevant domestic and international guidelines. Currently, the integrase inhibitors on the market are the early generation elvitegravir (EVG) and raltegravir (RAL), the second generation dolutegravir (DTG) that have been launched in recent years, the compound bituvir containing bictegravir (BIC), and the long-acting form of cabotegravir (CAB).
[0006] The early integrase inhibitors had a low resistance barrier, with one or two mutations reducing viral sensitivity and high cross-resistance. Subsequent drugs such as dolutegravir had a high resistance barrier and have been widely used since their launch. Although integrase inhibitors have a high resistance barrier, like protease inhibitors and reverse transcriptase inhibitors, resistance is inevitable.
[0007] With current medical technology, once infected with HIV, one needs to take medication for life. Lifelong treatment has become the long-term goal of highly active antiretroviral therapy (HARRT), but there are still many issues to consider, and drug resistance is an issue that cannot be ignored and is a key factor affecting the success of HARRT.
[0008] Therefore, it is necessary to develop new integrase inhibitors to improve oral bioavailability, improve clinical toxicity and side effects, and enhance the barrier to drug resistance, which is of great significance to provide patients with better drug options and better compliance.
[0009] In view of this, the present invention is proposed. Summary of the invention
[0010] The purpose of the present invention is to provide a polycyclic carbamoyl pyridone derivative and a preparation method and a pharmaceutical composition thereof. The polycyclic carbamoyl pyridone derivative can selectively inhibit the activity of HIV integrase and can then be used to prevent and treat HIV infection.
[0011] The present invention is achieved in that:
[0012] In a first aspect, the present invention provides a polycyclic aminoformyl pyridone derivative, which includes a compound represented by formula (I)-1 or formula (I)-2, an isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof,
[0013]
[0014] wherein R1, R2, R3, R4, R5 and R6 are each independently selected from any one of hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -OR7, substituted or unsubstituted aryl, substituted or unsubstituted monocyclic heteroaryl ring, substituted or unsubstituted monocyclic heterocycle and cyano;
[0015] At least one of the following functional groups (1) to (3) and the carbon atom connected to the A ring forms a spiro ring or a spiroheterocycle:
[0016] (1) R1 and R2; (2) R3 and R4; (3) R5 and R6; that is, when the polycyclic aminoformyl pyridone derivative is a compound represented by formula (I)-1, the functional group formed by R1 and R2 or the functional group formed by R3 and R4 and the carbon atom connected to the A ring form a spiro ring or a spiro heterocycle; when the polycyclic aminoformyl pyridone derivative is a compound represented by formula (I)-2, the functional group formed by R1 and R2 or the functional group formed by R5 and R6 and the carbon atom connected to the A ring form a spiro ring or a spiro heterocycle.
[0017] R7 is selected from any one of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl and substituted or unsubstituted alkynyl;
[0018] m is any natural number between 0 and 5. When m is 0, it indicates that ring A is a 5-membered ring.
[0019] In a second aspect, the present invention provides a method for preparing the polycyclic aminoformyl pyridone derivative according to any one of the aforementioned embodiments, wherein the polycyclic aminoformyl pyridone derivative is synthesized according to the following synthesis route:
[0020]
[0021] In a third aspect, the present invention provides a pharmaceutical composition comprising the polycyclic aminoformyl pyridone derivative according to any one of the aforementioned embodiments, its isomer, pharmaceutically acceptable salt, hydrate or solvate and a pharmaceutically acceptable carrier thereof.
[0022] The present invention has the following beneficial effects:
[0023] 1. The polycyclic aminoformyl pyridone derivatives of the present invention can selectively inhibit the activity of HIV integrase, and can be widely used in the prevention and treatment of AIDS infection;
[0024] 2. It has excellent permeability and PK properties, which is conducive to drug development, can also reduce the number of dosing times and increase patient compliance with medication;
[0025] 3. It has lower cytotoxicity, improves medication safety, and reduces the risk of adverse reactions. DETAILED DESCRIPTION
[0026] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0027] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, which includes a compound represented by formula (I)-1 or formula (I)-2, an isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof,
[0028]
[0029] wherein R1, R2, R3, R4, R5 and R6 are independently selected from any one of hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -OR7, substituted or unsubstituted aryl, substituted or unsubstituted monocyclic heteroaryl ring, substituted or unsubstituted monocyclic heterocycle and cyano; and at least one of the following functional groups (1)-(3) and the carbon atom connected to the A ring forms a spiro ring or spiroheterocycle: (1) R1 and R2; (2) R3 and R4; (3) R5 and R6; R7 is selected from any one of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl and substituted or unsubstituted alkynyl; and m is any natural number between 0 and 5.
[0030] Further, R1, R2, R3, R4, R5 and R6 are each independently selected from any one of hydrogen, halogen, C1-4 alkyl, halogenated C1-C4 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR5, C3-C8 cycloalkyl, C6-C10 aryl, 5-6 membered monocyclic heteroaryl ring, 4-6 membered saturated monocyclic heterocycle and cyano; and at least one group of the following functional groups (1)-(3) and the carbon atom connected to the A ring form a 3-8 membered spiro ring or a 3-8 membered spiro heterocycle: (1) R1 and R2; (2) R3 and R4; (3) R5 and R6; R7 is selected from any one of hydrogen, C1-4 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and halogenated C1-C4 alkyl; m is 0, 1, 2 or 3.
[0031] Further, the tertiary carbon atom connected to the A ring and the pyrazine ring in the compounds shown in formula (I)-1 and formula (I)-2 has chirality; the configuration of the compounds shown in formula (I)-1 and formula (I)-2 can be a single configuration or a mixture of multiple configurations. And the isomers include at least one of tautomers, cis-trans isomers, meso compounds and optical isomers with enantiomeric or diastereomeric relationships. Specifically, the tertiary carbon atom connected to the A ring and the pyrazine ring has an S configuration.
[0032] Further, R1 and R2 are selected from C1-4 alkyl and C3-C5 cycloalkyl, specifically methyl and cyclopropyl, wherein methyl is more specifically in R configuration; R3 and R4 are selected from hydrogen, C3-C6 cycloalkyl and C3-C6 cycloheteroalkyl, specifically hydrogen, cyclopropyl, cyclopentyl, cyclohexyl and 6-membered oxygen-containing cycloheteroalkyl; R5 and R6 are selected from hydrogen, C3-C6 cycloalkyl and C3-C6 cycloheteroalkyl, specifically hydrogen, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and 6-membered oxygen-containing cycloheteroalkyl.
[0033] Furthermore, the polycyclic aminoformyl pyridone derivative is selected from any one of the compounds represented by the following structural formulas:
[0034]
[0035] Preferably,
[0036] The terms mentioned in the embodiments of the present invention have the following meanings:
[0037] "Halogen" refers to fluorine, chlorine, bromine and iodine.
[0038] The "C1-C4 alkyl group" is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl.
[0039] "Cycloalkyl" is a monovalent group derived from a monocyclic or polycyclic saturated or partially unsaturated aliphatic carbocyclic cyclic compound. C3-C8 cycloalkyl includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
[0040] cyclooctyl, cyclooctenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl.
[0041] "Alkenyl" is a monovalent group derived from a hydrocarbon group. C2-C6 alkenyl refers to an alkenyl group containing 2 to 6 carbon atoms and at least one carbon-carbon double bond, including but not limited to ethenyl, propenyl, butenyl, 2-methyl-2-butene, 2-methyl-2-pentene and similar groups.
[0042] "Alkynyl" refers to an alkynyl group containing 2 to 6 carbon atoms and at least one carbon-carbon triple bond, including, but not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, and the like.
[0043] "Aryl" is an aromatic cyclic hydrocarbon group having one or more aromatic rings, a fused or non-fused carbon ring system, for example, phenyl and naphthyl. "Aryl" may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylamino, halogen, thiol, hydroxyl, nitro or cyano.
[0044] "Heteroaryl" is a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms selected from N, S or O, or a bicyclic heteroaryl fused with a benzene ring, a pyridine ring or a pyrrole ring, which may be partially saturated, for example: pyridyl, pyrimidinyl, furanyl, etc.
[0045] "Spirocycle" refers to a polycyclic group in which one carbon atom is shared between the single rings, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Spirocycles are divided into bispirocycles or polyspirocycles according to the number of rings, preferably bispirocycles.
[0046] "Spiro heterocycle" refers to a polycyclic hydrocarbon with one atom shared between the single rings, wherein one or two ring atoms are selected from heteroatoms of NR6 (R6 is hydrogen, oxygen, alkyl or haloalkyl), oxygen or S(O)n (n is 0, 1 or 2), wherein the nitrogen and the remaining ring atoms are carbon. These may contain one or more double bonds, but none of the rings has a completely conjugated π electron system. Spiro heterocycles are classified into bispiro heterocycles or polyspiro heterocycles according to the number of rings, preferably bispiro heterocycles.
[0047] "Pharmaceutically acceptable salts" are relatively non-toxic acid addition salts or base addition salts of the compounds provided in the embodiments of the present invention. The acid addition salts are salts formed by the compounds of formula (I)-1 or (I)-2 provided in the embodiments of the present invention and a suitable inorganic acid or organic acid, for example: hydrochloride, fumarate, etc.
[0048] The base addition salt is a salt formed by the compound represented by formula (I)-1 or (I)-2 provided in the embodiment of the present invention and a suitable inorganic base or organic base, for example, sodium salt, methylamine salt, etc.
[0049] In a second aspect, an embodiment of the present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, and the polycyclic aminoformyl pyridone derivative is synthesized according to the following synthesis route:
[0050]
[0051] That is, the preparation process of the compound represented by formula (I)-1 or (I)-2 provided in the embodiment of the present invention is as follows: compound II is used as the starting material, and compound III-1 or III-2 is reacted with it under acid catalysis to obtain intermediate IV-1 or IV-2 through intramolecular ring closure, and intermediate IV-1 or 2 is subjected to demethylation reaction.
[0052] The compound represented by the general formula (II) can be prepared by the method provided in Organic Letter, 2015, 17, 564-567, or by other conventional methods in the art.
[0053] When preparing intermediate IV-1 or IV2, the acid catalyst used is an organic acid catalyst or an inorganic acid catalyst, such as formic acid, acetic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, magnesium sulfate, sodium sulfate, 4A molecular sieve or magnesium trifluoromethanesulfonate, etc., preferably acetic acid.
[0054] Specifically, the conditions for preparing intermediate IV-1 include: the molar ratio of compound II to compound III-1 is 1:1-1:5, preferably 1:1.5-1:3; the molar ratio of compound II to acid catalyst is 1:1-1:10, preferably 1:4-1:8; the temperature is 30-100°C; preferably 60-80°C; the reaction solvent is acetonitrile, toluene, etc., preferably acetonitrile; the time is 5 minutes to 16 hours;
[0055] The conditions for preparing intermediate IV-2 include: the molar ratio of compound II to compound III-2 is 1:1-1:5, preferably 1:1.5-1:3; the molar ratio of compound II and acid catalyst is 1:1-1:10, preferably 1:4-1:8; the temperature is 30-100°C; preferably 60-80°C; the reaction solvent is acetonitrile, toluene, etc., preferably acetonitrile; the time is 5 minutes to 16 hours.
[0056] When preparing the compound represented by general formula (I)-1 or (I)-2, the demethylation agent is: boron tribromide, sodium bromide, sodium iodide, magnesium bromide, lithium bromide, magnesium chloride, preferably lithium bromide.
[0057] Specifically, the conditions for preparing the compound represented by general formula (I)-1 include: the molar ratio of intermediate IV-1 and demethylation agent is 1:1-1:10, preferably 1:4-1:6; the reaction temperature is 30-100°C, preferably 50-70°C; the reaction solvent is dichloromethane, tetrahydrofuran, etc., preferably tetrahydrofuran; the reaction time is several minutes to several hours, preferably 5 minutes to 16 hours.
[0058] The conditions for preparing the compound represented by general formula (I)-2 include: the molar ratio of intermediate IV-2 and demethylation agent is 1:1-1:10, preferably 1:4-1:6; the reaction temperature is 30-1:100°C, preferably 50-70°C; the reaction solvent is dichloromethane, tetrahydrofuran, etc., preferably tetrahydrofuran; the reaction time is several minutes to several hours, preferably 5 minutes to 16 hours.
[0059] In a third aspect, the present invention provides a pharmaceutical composition, comprising the polycyclic aminoformyl pyridone derivative, its isomer, pharmaceutically acceptable salt, hydrate or solvate and a pharmaceutically acceptable carrier thereof according to any one of the aforementioned embodiments, wherein the pharmaceutically acceptable carrier is selected from water for injection, lyophilized powder excipients or oral preparation excipients.
[0060] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0061] Example 1
[0062] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: Named as: (4R,12aS)-N-(2,4-difluorophenyl)-7-hydroxy-4-methyl-6,8-dioxo-6,8,12,12a-tetrahydro-2H,4H-spiro[cyclopropane-1,3-pyrido[1,2:4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide.
[0063] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0064] Preparation of intermediate 1a:
[0065]
[0066] Step 1: Add thionyl chloride (20.4 g, 172 mmol) to 160 mL of methanol, cool to 0°C, add compound 1a.1 (12 g, 116 mmol) dropwise to the reaction solution, stir and react at room temperature for 5 h, and after the reaction is completed, concentrate under reduced pressure to remove the solvent to obtain a concentrate. Add methanol / dichloromethane (1:1) to the concentrate and continue to concentrate several times to remove the remaining thionyl chloride to obtain an off-white solid 1a.2 (14.8 g).
[0067] 1 H NMR (400MHz, CDCl3) δ8.34 (br s, 3H), 3.79 (br s, 1H), 3.69 (s, 3H), 2.95 (d, J = 15.9Hz, 1H), 2.72 (d, J = 15.8Hz, 1H), 1.46 (s, 3H); 13 C NMR (100MHz, CDCl3) δ171.0, 52.4, 45.1, 38.2, 18.7.
[0068] Step 2: Compound 1a.2 (10 g, 65 mmol) and sodium bicarbonate (35.8 g, 426.8 mmol) were added to a mixed solvent of 120 mL tetrahydrofuran and 80 mL DMSO, and finally benzyl bromide (29.2 g, 170.7 mmol) was added, and the mixture was stirred at 90-100°C for 12 h. After cooling to room temperature, water and ethyl acetate were added to quench, and the organic layer was separated, and the mixture was washed with saturated sodium chloride solution and dried with anhydrous sodium sulfate. Purification was performed by silica gel column chromatography, eluted with ethyl acetate and petroleum ether (1:19), and a white solid 1a.3 (19 g, 98%) was obtained.
[0069] 1 H NMR (400MHz, CDCl3) δ7.40-7.28(m,8H),7.27-7.21(m,2H),3.69(d,J=13.7Hz,2H),3.63(s,3H),3.47(d,J=13. 7Hz,2H),3.40-3.28(m,1H),2.68(dd,J=14.0,8.1Hz,1H),2.32(dd,J=14.0,6.9Hz,1H),1.13(d,J=6.7Hz,3H). 13 C NMR (100MHz, CDCl3) δ172.8,140.1,128.9,128.2,126.9,53.4,51.5,50.9,39.2,14.0.
[0070] Step 3: Compound 1a.3 (0.5 g, 1.7 mmol) was added to 4 mL of anhydrous THF, and the mixture was cooled to -78 °C under nitrogen protection. 2.6 mL of LDA (2 M THF solution, 3.0 equiv.) was added dropwise. After stirring for 1-2 h, the terminal substituted bromochloroalkane was added dropwise at -78 °C. The compound of Example 1 selected n=1 as 1-bromo-2-chloroethane (1.45 g, 10.1 mmol, 6 equiv.). After the addition, the mixture was transferred to room temperature and stirred for 24 h. Ammonium chloride solution was added to quench the mixture, and the mixture was extracted with ethyl acetate, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a mixture. The mixture was purified by silica gel column chromatography, eluted with ethyl acetate and petroleum ether (1:19) to obtain an oily substance 1a.4 (0.9 g), which was directly used in the next step.
[0071] Step 4: Compound 1a.4 (0.8 g) was added with 5 mL THF and DMPU (1:1) without water, cooled to -78 ° C under nitrogen atmosphere, and 5.6 mL LiHMDS (1 M THF solution, 2.5 equiv.) was added dropwise. After the addition, the reaction was stirred at room temperature for 4-5 h. Ammonium chloride solution was added to quench, extracted with ethyl acetate, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a mixture. Purification was performed by aluminum oxide column chromatography and elution with ethyl acetate: petroleum ether (1:19) to obtain a colorless oil 1a.5 (0.43 g, two-step yield 30%).
[0072] 1H NMR(400MHz, CDCl3) δ7.32-7.16(m,10H),3.85(d,J=13.6Hz,2H),3.55(s,3H),3.40(d,J=13.6Hz,2H), 3.37(q,J=6.9Hz,1H),1.30-1.21(m,1H),0.96(d,J=6.9Hz,3H),0.89-0.76(m,2H),0.63-0.54(m,1H).
[0073] Step 5: Compound 1a.5 (0.42 g) was added with 10 mL of anhydrous ether, cooled to 0°C under nitrogen atmosphere, and lithium aluminum tetrahydride (75 mg, 1.96 mmol, 1.5 equiv.) was added and stirred for 2-3 h. After the reaction, water was slowly added at 0°C to quench, extracted with ethyl acetate, washed with sodium chloride, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by aluminum oxide column chromatography with ethyl acetate and petroleum ether (1:9) to obtain a colorless oil 1a.6 (0.25 g, 65%).
[0074] 1 H NMR (400MHz, CDCl3) δ7.44-7.20(m,10H),4.01(d,J=13.0Hz,2H),3.52(dd,J=11.2,1.7Hz,1H),3.37(q,J=6.8Hz,1H),3.30(d,J=13. 0Hz,2H),3.19(d,J=11.2Hz,1H),0.80(d,J=6.8Hz,3H),0.82-0.72(m,1H),0.69-0.61(m,1H),0.33-0.23(m,1H),0.13-0.05(m,1H); 13 C NMR (100MHz, CDCl3) δ139.0,129.4,128.7,127.4,72.3,55.5,54.1,22.9,7.0,6.5,5.9.
[0075] Step 6: Compound 1a.6 (0.25 g, 0.84 mmol) was added to 5 mL of methanol, and 80 mg of Pd(OH)2 / C (20% carbon-loaded 50% water) was added. The mixture was stirred at room temperature under a hydrogen atmosphere (balloon) for 12 h. After the reaction was completed, the carbon was removed by filtration with the aid of diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain a colorless oil compound 1a (90 mg, 93%).
[0076] 1H NMR (400MHz, CDCl3) δ4.18(dd,J=11.2,1.8Hz,1H),3.48(s,1H),2.94(dd,J=11.3,1.3Hz,1H),2.61(q d,J=6.6,1.2Hz,1H),1.23(d,J=6.6Hz,3H),0.69-0.60(m,1H),0.51-0.42(m,1H),0.33-0.20(m,2H); 13 C NMR (100MHz, CDCl3) δ68.4, 54.8, 25.7, 19.9, 11.4, 7.6.
[0077] Preparation of intermediate 1b:
[0078]
[0079] Step 1: Compound 1b.1 (50 g, 158.6 mmol) and N,N'-carbonyldiimidazole (30.8 g, 190.3 mmol) were added to 500 mL of acetonitrile, and the mixture was stirred under nitrogen protection and heated to reflux for 2-3 h. The mixture was cooled to 0-10 °C, and a mixed solution of 2,4-difluorobenzylamine (27.2 g, 190.3 mmol) and 30 mL of acetonitrile was slowly added dropwise. After the addition was complete, the mixture was reacted at room temperature for 1 h. After the reaction was completed, 200 mL of water was added to quench the mixture, and the acetonitrile was removed by rotary evaporation under reduced pressure. 300 mL of ethyl acetate was added to dilute the mixture, and the mixture was washed with 300 mL of 2M hydrochloric acid and saturated sodium bicarbonate solution twice, respectively, and dried over anhydrous sodium sulfate. The mixture was concentrated under reduced pressure to obtain a light yellow solid, which was then washed with ether and dried to obtain an off-white solid 1b.2 (53.4 g, 77%).
[0080] 1 H NMR (400MHz, CDCl3) δ10.39 (t, J = 5.4Hz, 1H), 8.42 (s, 1H), 7.41-7.35 (m, 1H), 6.85-6.77 (m, 2H), 4.62 (d,J=5.6Hz,2H),4.50(t,J=4.8Hz,1H),4.04(d,J=4.8Hz,2H),3.99(s,3H),3.96(s,3H),3.39(s,6H).
[0081] Step 2: Compound 1b.2 (20 g, 45.4 mmol) was added to 100 mL of formic acid and stirred at 60 °C for 3 h. After the reaction, the solvent was removed by rotary evaporation. The mixture was diluted with acetonitrile and concentrated repeatedly for several times. 80 mL of methyl tert-butyl ether was added and stirred for crystallization for 10-12 h. The mixture was filtered and dried to obtain a white solid 1b (17.2 g).
[0082] 1H NMR (400 MHz, DMSO-d6) (hydrate) δ 10.31 (t, J = 5.8 Hz, 1H), 8.46 (s, 1H), 7.45-7.39 (m, 1H), 6.28-6.72 (m, 1H), 7.10-7.05 (m, 1H), 6.39 (d, J = 5.8 Hz, 2H), 4.96 (t, J = 5.6 Hz, 1H), 4.53 (d, J = 5.7 Hz, 2H), 3.95 (d, J = 5.1 Hz, 2H), 3.93 (s, 3H), 3.81 (s, 3H).
[0083] Compound 1b is the acetal deprotection product ( 1 H NMR showed that the hydrate was the main form). Regardless of the structural form, it does not affect the ring-closing reaction. In the following examples, compound 1b (MW: 412.1) was measured based on the hydrate.
[0084] Preparation of compound 1
[0085]
[0086] Step 1: Compound 1b (160 mg, 0.39 mmol), compound 1a (90 mg, 0.78 mmol) and acetic acid (140 mg, 2.34 mmol) were added to 2 mL of acetonitrile and stirred at 70-80°C for 5-6 h. After the reaction, sodium bicarbonate aqueous solution was added for washing, ethyl acetate was extracted, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 1c, which was directly used in the next step. MS m / z (ESI): 460.2 [M+1] + .
[0087] Step 2: Add intermediate 1c to anhydrous THF, add LiBr (4.0 equiv.) and stir at 70-80°C for 5-6h. After the reaction, quench with 0.5M sulfuric acid solution, add ethyl acetate for extraction, wash with sodium bicarbonate solution, dry and concentrate with anhydrous sodium sulfate to obtain a mixture. Separate by silica gel column chromatography, elute with dichloromethane / methanol gradient, and purify to obtain compound 1 (off-white solid, 128 mg, two-step yield 74.0%). MS m / z (ESI): 446.2 [M+1] + .
[0088] 1H NMR(400MHz,DMSO-d6)δ12.51(br s,1H),10.36(t,J=5.9Hz,1H),8.53(s,1H),7.42-7.36(m,1H),7.27-7.21(m,1H),7 .09-7.04(m,1H),5.53(t,J=4.6Hz,1H),4.59(dd,J=14.1,3.9Hz,1H),4.55(d,J=5.9 Hz,2H),4.49(dd,J=14.0,5.0Hz,1H),4.33(d,J=11.8Hz,1H),4.09(q,J=6.9Hz,1H), 3.10(d,J=11.8Hz,1H),1.37(d,J=7.0Hz,3H),0.56-0.52(m,3H),0.44-0.42(m,1H).
[0089] Example 2
[0090] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: Named as: (4'R,12a'S)-N-(2,4-difluorophenyl)-7'-hydroxy-4'-methyl-6',8'-dioxo-66',8',12',12a'-tetrahydro-2'H,4'H-spiro[cyclobutane-1,3'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]pyrazine]-9'-carboxamide.
[0091] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0092] Intermediate 2a Preparation: Referring to the synthesis of intermediate 1a in Example 1, wherein the bromochloroalkane in step 3 is selected as 1-bromo-3-chloro-propane with n=2, and the cyclobutane spiro intermediate is obtained by LDA catalytic substitution and LiHMDS cyclization, followed by reduction and deprotection reaction to obtain intermediate 2a (colorless oil, 490 mg).
[0093] 1 H NMR (400MHz, CDCl3) δ3.89 (dd, J=11.1, 1.2Hz, 1H), 3.67 (dd, J=11.0, 1.2Hz, 1H), 3.43 (s, 1H), 3.29 (qd, J=6.6, 1.2Hz,1H),2.15-2.00(m,1H),1.97-1.75(m,3H),1.71-1.60(m,1H),1.52-1.41(m,1H),1.01(d,J=6.6Hz,3H); 13C NMR (100MHz, CDCl3) δ67.9,55.5,44.4,27.9,26.3,16.8,14.9.
[0094] Synthesis of compound 2:
[0095]
[0096] Step 1: Compound 1b (412 mg, 1 mmol), compound 2a (260 mg, 2 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and stirred at 70-80°C for 6-7 h. After the reaction, sodium bicarbonate aqueous solution was added for washing, ethyl acetate was extracted, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 2c, which was directly used in the next step. MS m / z (ESI): 474.2 [M+1] + .
[0097] Step 2: Intermediate 2c was added to anhydrous THF, LiBr (4.0 equiv.) was added, and the reaction was stirred at 70-80°C for 7-8h. After the reaction was completed, 0.5M sulfuric acid solution was quenched, ethyl acetate was added for extraction, sodium bicarbonate solution was washed, and anhydrous sodium sulfate was dried and concentrated to obtain a mixture. Silica gel column chromatography was used for separation and dichloromethane / methanol gradient elution to purify compound 2 (off-white solid, 260 mg, two-step yield 56.6%). MS m / z (ESI): 460.2 [M+1] + .
[0098] 1 H NMR(400MHz,CDCl3)δ12.48(br s,1H),10.38(t,J=5.84Hz,1H),8.32(s,1H),7.39-7.33(m,1H),6.84-6.77(m,2H),5. 18(dd,J=6.0,4.1Hz,1H),4.88(q,J=7.0Hz,1H),4.65(dd,J=15.9,6.1Hz,1H),4.61(d d,J=15.9,6.0Hz,1H),4.28(dd,J=13.6,4.1Hz,1H),4.12(dd,J=13.5,5.9Hz,1H),3.9 2(d,J=12.2Hz,1H),3.87(d,J=11.8Hz,1H),2.07-1.55(m,6H),1.23(d,J=7.0Hz,3H).
[0099] Example 3
[0100] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: Named as: (4'R,12a'S)-N-(2,4-difluorophenyl)-7'-hydroxy-4'-methyl-6',8'-dioxo-6',8',12',12a'-tetrahydro-2'H,4'H-spiro[cyclopentane-1,3'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide.
[0101] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0102] Intermediate 3a Preparation: Referring to the synthesis of intermediate 1a in Example 1, wherein in step 3, the bromochloroalkane selected as n=4 is 1-bromo-4-chloro-butane, which is successively catalyzed by LDA and cyclized under LiHMDS to obtain a cyclopentane spiro intermediate, and then reduced and deprotected to obtain intermediate 3a (colorless oil, 320 mg).
[0103] 1 H NMR (400MHz, CDCl3) δ3.73(dd,J=10.9,1.3Hz,1H),3.45(s,1H),3.34(dd,J=10.9,1.3Hz,1H),3.06(q d,J=6.6,1.3Hz,1H),2.01-1.89(m,1H),1.72-1.50(m,4H),1.40-1.20(m,3H),1.18(d,J=6.6Hz,3H); 13 C NMR (100MHz, CDCl3) δ68.1,56.6,49.5,33.7,32.1,25.3,25.2,19.0.
[0104] Synthesis of compound 3:
[0105]
[0106] Step 1: Compound 1b (412 mg, 1 mmol), compound 3a (311 mg, 2.17 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and stirred at 70-80°C for 6-7 h. After the reaction, sodium bicarbonate aqueous solution was added for washing, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 3c, which was directly used in the next step. MS m / z (ESI): 488.2 [M+1] + .
[0107] Step 2: The intermediate 3c was added to anhydrous THF, and LiBr (5.0 equiv.) was added to react at 70-80°C with stirring for 8 h. LiBr (5.0 equiv.) was added to react for 12 h. After the reaction was completed, 0.5 M sulfuric acid solution was added to quench, ethyl acetate was added to extract, sodium bicarbonate solution was washed, and the mixture was dried over anhydrous sodium sulfate and concentrated to obtain a mixture. Silica gel column chromatography was used for separation and dichloromethane / methanol gradient elution to purify compound 2 (light yellow solid, 170 mg, two-step yield 36.0%). MS m / z (ESI): 474.2 [M+1] + .
[0108] 1 H NMR(400MHz,CDCl3)δ12.48(br s,1H),10.40(t,J=5.8Hz,1H),8.33(s,1H),7.39-7.33(m,1H),6.84-6.77(m,2H),5.24(dd,J=6.1,4.2Hz,1H),4.69-4.59(m,3H),4.28(dd, J=13.6,4.2Hz,1H),4.13(dd,J=13.5,6.2Hz,1H),3.82(d,J=11.2Hz,1H),3.56(d,J=11.6Hz,1H),1.87-1.16(m,8H),1.33(d,J=7.04Hz,3H).
[0109] Example 4
[0110] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: Named as: (4'R,12a'S)-N-(2,4-difluorophenyl)-7'-hydroxy-4'-methyl-6',8'-dioxo-6',8',12',12a'-tetrahydro-2'H,4'H-spiro[cyclohexane-1,3'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide.
[0111] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0112] Intermediate 4a Preparation: Referring to the synthesis of intermediate 1a in Example 1, wherein in step 3, the bromochloroalkane selected as n=5 is 1-bromo-5-chloro-pentane, which is successively catalyzed by LDA and cyclized under LiHMDS to obtain a cyclohexane spiro intermediate, followed by reduction and deprotection reactions to obtain intermediate 4a (colorless oil, 130 mg).
[0113] 1H NMR (400MHz, CDCl3) δ3.77(d,J=11.1Hz,1H),3.59(dd,J=11.2,1.4Hz,1H),3.03(qd,J=6.6,1.4Hz,1H ),1.93-1.80(m,1H),1.63-1.39(m,4H),1.35-1.25(m,4H),1.14(d,J=6.6Hz,3H),1.08-0.97(m,1H); 13 C NMR (100MHz, CDCl3) δ66.5,55.6,38.5,30.9,30.4,26.4,21.7,21.5,17.4.
[0114] Synthesis of compound 4:
[0115]
[0116] Step 1: Compound 1b (173 mg, 0.42 mmol), compound 4a (130 mg, 0.84 mmol) and acetic acid (185 mg, 2.5 mmol) were added to 2 mL of acetonitrile and stirred at 70-80°C for 7-8 hours. After the reaction, sodium bicarbonate aqueous solution was added for washing, ethyl acetate was extracted, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 4c, which was directly used in the next step. MS m / z (ESI): 502.2 [M+1] + .
[0117] Step 2: Intermediate 4c was added to anhydrous THF, LiBr (4.0 equiv.) was added, and the reaction was stirred at 70-80°C for 22 h. After the reaction was completed, 0.5 M sulfuric acid solution was added to quench, ethyl acetate was added to extract, sodium bicarbonate solution was washed, and the mixture was dried over anhydrous sodium sulfate and concentrated to obtain a mixture. Silica gel column chromatography was used for separation and dichloromethane / methanol gradient elution to purify compound 4 (light yellow solid, 90 mg, two-step yield 43.9%). MS m / z (ESI): 488.2 [M+1] + .
[0118] 1H NMR (400 MHz, CDCl3) δ 12.52 (br s,1H),10.41(t,J=8.96Hz,1H),8.36(s,1H),7.38-7.35(m,1H),6.84-6.7 7(m,2H),5.17(t,J=4.8Hz,1H),4.87(q,J=7.0Hz,1H),4.68-4.58(m,2H),4 .32(dd,J=13.6,3.8Hz,1H),4.15(dd,J=13.6,5.4Hz,1H),3.73(d,J=12.0H z, 1H), 3.67 (d, J = 12.0Hz, 1H), 1.57-1.08 (m, 10H), 1.31 (d, J = 7.08Hz, 3H).
[0119] Example 5
[0120] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below:
[0121] Named as: (4'R,12a'S)-N-(2,4-difluorophenyl)-7'-hydroxy-4'-methyl-6',8'-dioxo-2,3,5,6,6',8',12',12a'-octahydro-2'H,4'H-spiro[pyran-4,3'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide.
[0122] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0123] Intermediate 5a Preparation: Referring to the synthesis of intermediate 1a in Example 1, the bromochloroalkane in step 3 is 1-bromo-2-(2-chloroethoxy)ethane, which is successively catalyzed by LDA and ring-closed under the action of LiHMDS to obtain a pyranospiro intermediate, and then reduced and deprotected to obtain intermediate 4a (colorless oil, 0.29 g).
[0124] 1H NMR (400MHz, CDCl3) δ3.80-3.75(m,3H),3.74-3.68(m,1H),3.64(td,J=11.8,2.6Hz,1H),3.43(td,J=11.8,3.0Hz,2H),2. 13C NMR (100MHz, CDCl3) δ64.1, 63.68, 63.65, 57.1, 36.6, 30.5, 17.0.
[0125] Synthesis of compound 5:
[0126]
[0127] Step 1: Compound 1b (412 mg, 1 mmol), compound 5a (270 mg, 1.7 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and stirred at 70-80°C for 7-8 hours. After the reaction, sodium bicarbonate aqueous solution was added for washing, ethyl acetate was extracted, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 5c, which was directly used in the next step. MS m / z (ESI): 504.2 [M+1] + .
[0128] Step 2: Intermediate 5c was added to anhydrous THF, and LiBr (4.0 equiv.) was added and stirred at 70-80°C for 21 h. After the reaction was completed, 0.5 M sulfuric acid solution was added to quench, ethyl acetate was added for extraction, sodium bicarbonate solution was washed, and anhydrous sodium sulfate was dried and concentrated to obtain a mixture. Silica gel column chromatography was used for separation and dichloromethane / methanol gradient elution to purify compound 4 (light yellow solid, 72 mg, two-step yield 14.7%). MS m / z (ESI): 490.2 [M+1] + .
[0129] 1H NMR(400MHz,CDCl3)δ12.38(br s,1H),10.37(t,J=5.9Hz,1H),8.38(s,1H),7.38-7.32(m,1H),6.84-6.77(m,2H),5.21(t,J=5. 2Hz,1H),4.91(q,J=7.0Hz,1H),4.65(dd,J=16.3,5.1Hz,1H),4.61(dd,J=16.6,5.1Hz,1H),4.1 7(dd,J=13.7,4.1Hz,1H),3.98(d,J=12.1Hz,1H),3.88(d,J=12.1Hz,1H),3.80-3.55(m,4H),1. 78-1.72(m,1H),1.64-1.59(m,1H),1.54-1.48(m,1H),1.34(d,J=7.1Hz,3H),1.32-1.29(m,1H).
[0130] Example 6
[0131] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: Named as: (4'R,12a'S)-N-(2,4-difluorophenyl)-7'-hydroxy-4'-methyl-6',8'-dioxo-3',4',6',8',12',12a'-hexahydrospiro[cyclopropane-1,2'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide.
[0132] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0133] Preparation of intermediate 6a:
[0134]
[0135] Step 1: Compound 1a.3 (500 mg, 1.7 mmol) was added to anhydrous THF (10 mL), cooled to -30 °C under nitrogen protection, and Ti(O i Pr)4 (0.25 equiv.), EtMgbr s (3M / Et2O, 3.0 equiv.), transferred to room temperature and stirred for 10-12 h. After the reaction was completed, ammonium chloride solution was added to quench, extracted with ethyl acetate, washed with sodium chloride solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. Alumina column chromatography was used for separation, and ethyl acetate and petroleum ether (1:9) were used for elution to obtain intermediate 6a.1 (colorless oil, 254 mg, 51%).
[0136] 1 H NMR (400MHz, CDCl3) δ7.40-7.19(m,10H),6.78(s,1H),3.99(d,J=12.9Hz,2H),3.38-3.24(m,1H),3.28(d,J=12.9Hz,2H),2.52(ddd,J=1 4.3,12.4,1.9Hz,1H),1.07(d,J=6.7Hz,3H),0.77(dd,J=14.6,2.9Hz,1H),0.74-0.65(m,1H),0.39-0.22(m,2H),0.01-(-0.10)(m,1H); 13 C NMR (100MHz, CDCl3) δ138.5,129.5,128.5,127.4,56.6,53.6,53.3,40.1,12.7,12.6,12.0.
[0137] Step 2: The reaction of removing the Bn protecting group was carried out by referring to Step 6 of Compound 1a to obtain Compound 6a (colorless oil, 390 mg, ~100%).
[0138] 1 H NMR (400MHz, CDCl3) δ: 3.46 (s, 1H), 3.35-3.19 (m, 1H), 1.80 (ddd, J = 14.4, 9.9, 1.7Hz, 1H), 1.28-1.22 (m ,1H),1.17(d,J=6.4Hz,3H),0.82-0.73(m,1H),0.73-0.65(m,1H),0.50-0.38(m,1H),0.38-0.29(m,1H).
[0139] Preparation of compound 6:
[0140]
[0141] Step 1: Compound 1b (268 mg, 0.65 mmol), compound 6a (150 mg, 1.3 mmol) and acetic acid (234 mg, 3.9 mmol) were added to 3 mL of acetonitrile and stirred at 70-80°C for 6-8 hours. After the reaction, sodium bicarbonate aqueous solution was added for washing, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 6c, which was directly used in the next step. MS m / z (ESI): 460.2 [M+1] + .
[0142] Step 2: Intermediate 6c was added to anhydrous THF, LiBr (4.0 equiv.) was added, and the reaction was stirred at 70-80°C for 14 h. After the reaction was completed, 0.5 M sulfuric acid solution was added to quench, ethyl acetate was added to extract, sodium bicarbonate solution was washed, and anhydrous sodium sulfate was dried and concentrated to obtain a mixture. Silica gel column chromatography was used for separation and dichloromethane / methanol gradient elution to purify compound 4 (light yellow solid, 110 mg, two-step yield 38%). MS m / z (ESI): 446.2 [M+1] + .
[0143] 1 H NMR(400MHz,CDCl3)δ12.50(br s,1H),10.39(t,J=5.8Hz,1H),8.36(s,1H),7.38-7.32(m,1H),6.84-6.76(m,2H),5.21(t,J=5.2Hz, 1H),5.08-5.01(m,1H),4.63(dd,J=16.3,6.2Hz,1H),4.59(dd,J=16.0,6.1Hz,1H),4.35(dd,J=13.4 ,3.0Hz,1H),4.15(dd,J=12.5,5.0Hz,1H),2.62(dd,J=13.1,5.2Hz,1H),1.49(d,J=7.1Hz,3H),1.13 (dd,J=13.9,1.1Hz,1H),1.05-0.98(m,1H),0.88-0.82(m,1H),0.70-0.64(m,1H),0.56-0.50(m,1H).
[0144] Example 7
[0145] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: Named as: (4'R,12a'S)-N-(2,4-difluorophenyl)-7'-hydroxy-4'-methyl-6',8'-oxo-3',4',6',8',12',12a'-hexahydrospiro[cyclopentane-1,2'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide.
[0146] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0147] Preparation of intermediate 7a:
[0148]
[0149] Step 1: Magnesium chips (14.59 g, 600 mmol), iodine granules (0.91 g, 3.6 mmol) and 50 mL of anhydrous THF were added in sequence under a nitrogen atmosphere. Heat to 60°C, quickly add 1,2-dibromoethane (0.1 mL) and then add 1,4-dibromobutane (14.3 mL, 120 mmol), and stir to react for 1 h. After the reaction is completed, heat to 80°C and add intermediate 1a.3 (8.92 g dissolved in 20 mL of anhydrous THF, 30 mmol), and continue to stir and react at this temperature for 2 h. After the reaction is completed, add ammonium chloride solution to quench, filter to obtain the filtrate, extract with ethyl acetate, wash with sodium chloride solution, dry with anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a mixture. Separate by silica gel column chromatography, elute with ethyl acetate and petroleum ether to obtain intermediate 7a.3 (4.36 g of light yellow oil, 45%).
[0150] 1 H NMR (400MHz, CDCl3) δ7.34-7.29(m,8H),7.28-7.22(m,2H),6.70(s,1H),3.93( d,J=12.8Hz,2H),3.29-3.21(m,1H),3.21(d,J=12.8Hz,2H),2.18(dd,J=14.6,1 1.8Hz,1H),1.78-1.62(m,2H),1.60-1.51(m,1H),1.47-1.33(m,3H),1.13(dd,J =14.6,2.4Hz,1H),1.08(d,J=6.7Hz,3H),0.95-0.84(m,1H),0.80-0.71(m,1H). 13 C NMR (100MHz, CDCl3) δ138.39,129.76,128.45,127.33,82.41,52.88,51.46,42.37,41.53,38.08,23.96,23.47,12.39.
[0151] Step 2: Referring to the Bn removal synthesis operation of 1a, a white solid intermediate 7a was obtained, which was directly used in the next reaction. 1 HNMR (400MHz, CDCl3) δ3.21-3.08 (m, 1H), 1.88-1.40 (m, 10H), 1.13 (d, J = 6.4Hz, 3H); 13 C NMR (100MHz, CDCl3) δ82.2, 47.4, 46.5, 41.7, 39.2, 28.2, 24.1, 23.7.
[0152] Preparation of compound 7:
[0153]
[0154] Step 1: Compound 1b (346 mg, 0.84 mmol), compound 7a (300 mg, 2.1 mmol) and acetic acid (403 mg, 7.72 mmol) were added to 4 mL of acetonitrile and stirred at 70-80°C for 6 h. After the reaction, sodium bicarbonate aqueous solution was added for washing, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 7c, which was directly used in the next step. MS m / z (ESI): 488.2 [M+1] + .
[0155] Step 2: Intermediate 7c was added to anhydrous THF, LiBr (4.0 equiv.) was added, and the reaction was stirred at 70-80°C for 6 h. After the reaction was completed, 0.5 M sulfuric acid solution was added to quench, ethyl acetate was added to extract, sodium bicarbonate solution was washed, and anhydrous sodium sulfate was dried and concentrated to obtain a mixture. Silica gel column chromatography was used for separation and dichloromethane / methanol gradient elution to purify compound 4 (light yellow solid, 70 mg, two-step yield 17.6%). MS m / z (ESI): 474.2 [M+1] + .
[0156] 1 H NMR(400MHz,CDCl3)δ12.47(br s,1H),10.42(t,J=5.8Hz,1H),8.34(s,1H),7.40-7.34(m,1H),6.84-6.77(m,2H),5.35(t, J=3.4Hz,1H),4.83-4.75(m,1H),4.66(dd,J=15.3,6.0Hz,1H),4.60(dd,J=15.3,5.8Hz,1H ),4.30(dd,J=13.7,3.4Hz,1H),4.17(dd,J=13.7,3.5Hz,1H),2.11(dd,J=14.5,6.8Hz,1H) ,2.07-1.89(m,2H),1.83(dd,J=14.5,8.1Hz,1H),1.80-1.49(m,6H),1.39(d,J=6.8Hz,3H).
[0157] Example 8
[0158] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: Named as: (4'R,12a'S)-N-(2,4-difluorophenyl)-7'-hydroxy-4'-methyl-6',8'-oxo-3',4',6',8',12',12a'-hexahydrospiro[cyclohexane-1,2'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide.
[0159] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0160] Preparation of intermediate 8a:
[0161]
[0162] Step 1: Referring to the operating conditions of intermediate 7a.3, 1,5-dibromopentane was used to prepare intermediate 8a.3 (white solid, 2.68 g, 16%).
[0163] 1 H NMR (400MHz, CDCl3) δ7.35-7.30(m,8H),7.27-7.21(m,2H),6.62(s,1H),3.9 2(d,J=12.8Hz,2H),3.24–3.13(m,1H),3.19(d,J=12.8Hz,2H),1.81(dd,J=14 .8,12.0Hz,1H),1.70-1.58(m,1H),1.52(dd,J=12.9,5.6Hz,1H),1.46–1.32( m,3H),1.25–1.08(m,4H),1.05(d,J=6.7Hz,3H),0.71(dd,J=7.3,4.8Hz,2H). 13 C NMR (100MHz, CDCl3) δ138.50,129.90,128.52,127.40,71.51,52.95,49.18,42.67,40.60,35.77,26.14,22.24,22.13,12.52.
[0164] Step 2: Referring to the de-Bn operation conditions of intermediate 1a, a white solid intermediate 8a was prepared, which was directly used in the next reaction.
[0165] Synthesis of compound 8:
[0166]
[0167] Step 1: Compound 1b (412 mg, 1 mmol), compound 8a (300 mg, 2.2 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and stirred at 70-80°C for 16 h. After the reaction, sodium bicarbonate aqueous solution was added for washing, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 7c, which was directly used in the next step. MS m / z (ESI): 502.2 [M+1] + .
[0168] Step 2: Intermediate 8c was added to anhydrous THF, LiBr (4.0 equiv.) was added, and the reaction was stirred at 70-80°C for 6 h. After the reaction was completed, 0.5 M sulfuric acid solution was added to quench, ethyl acetate was added to extract, sodium bicarbonate solution was washed, and anhydrous sodium sulfate was dried and concentrated to obtain a mixture. Silica gel column chromatography was used for separation and dichloromethane / methanol gradient elution to purify compound 8 (light yellow solid, 194 mg, two-step yield 40.0%). MS m / z (ESI): 488.2 [M+1] + .
[0169] 1 H NMR(400MHz,CDCl3)δ12.40(br s,1H),10.48(t,J=5.9Hz,1H),8.42(s,1H),7.40-7.34(m,1H),6.85-6.77(m,2H),5.35(t,J=2.5Hz,1H),4.70-4.59(m,3H),4.28(dd,J=1 3.9,3.1Hz,2H),2.04(dd,J=15.0,6.9Hz,1H),1.80(dd,J=15.0,10.4Hz,1H),1.68-1.54(m,2H),1.44-1.21(m,8H),1.35(d,J=6.5Hz,3H).
[0170] Example 9
[0171] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: It is named (4R,12aS)-N-(2,4-difluorophenyl)-7'-hydroxy-4'-methyl-6',8'-dioxo-22,3,3',4',5,6,6',8',12',12a'-decahydrospiro[pyran-4,2'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide.
[0172] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0173] Preparation of intermediate 9a:
[0174]
[0175] Steps: The preparation method refers to the literature Tetrahedron Asymmetry 1996, 2911-2922, using (R)-2-aminopropanol as the raw material, after Bz amine protection and hydroxyl chlorination, tetrahydropyrone addition reaction in n-BuLi / Lithium naphthalenid system, and finally deprotection of Bz to obtain intermediate 9a. MS m / z (ESI): 160.23 [M+1] + .
[0176] 1 H NMR(DMSO-d6)δ3.64-3.48(m,4H),3.53-3.36(m,3H),3.12-2.85(m,1H),1.51-1.26(m,6H),1.02(d,J=6.4Hz,3H);
[0177] Synthesis of compound 9:
[0178]
[0179] Step 1: Compound 1b (412 mg, 1 mmol), compound 9a (318 mg, 2 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and stirred at 70-80°C for 10-12 h. After the reaction, sodium bicarbonate aqueous solution was added for washing, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 9c, which was directly used in the next step. MS m / z (ESI): 504.2 [M+1] + .
[0180] Step 2: Add intermediate 9c to anhydrous THF, add LiBr (4.0 equiv.), stir and react at 70-80°C for 6-8h, add 0.5M sulfuric acid solution to quench after the reaction, add ethyl acetate to extract, wash with sodium bicarbonate solution, dry and concentrate over anhydrous sodium sulfate to obtain a mixture. Separate by silica gel column chromatography, elute with dichloromethane / methanol gradient, and purify to obtain compound 9 (light yellow solid, 68 mg, two-step yield 13.9%). MS m / z (ESI): 490.2 [M+1] + .
[0181] 1H NMR(400MHz,CDCl3)δ12.31(br s,1H),10.40(t,J=5.8Hz,1H),8.36(s,1H),7.40-7.34(m,1H),6.85-6.77(m,2H),5.39(t,J=2.1Hz,1H),4 .74-4.60(m,3H),4.31(dd,J=13.9,3.0Hz,1H),4.24(dd,J=14.0,1.9Hz,1H),3.72-3.65(m,2H),3.60(dt, J=11.6,4.2Hz,1H),3.48(td,J=11.1,2.6Hz,1H),2.04(dd,J=15.0,6.9Hz,1H),1.90(dd,J=15.0,10.3Hz, 1H), 1.74-1.62 (m, 2H), 1.59 (dd, J=10.8, 4.7Hz, 1H), 1.55 (dd, J=10.8, 4.6Hz, 1H), 1.39 (d, J=6.5Hz, 3H).
[0182] Example 10
[0183] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below:
[0184] Named as: (3R,11aS)-N-(2,4-difluorophenyl)-6-hydroxy-3-methyl-5,7-dioxo-5,7,11,11a-tetrahydro-3H-spiro[cyclopropane-1,2-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8-carboxamide.
[0185] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0186] Preparation of intermediate 10a:
[0187]
[0188] Step 1: Under nitrogen atmosphere, compound 1a.1 (4.06 g, 20 mmol) was added to 40 mL of anhydrous THF, cooled to -30 to -35 °C, and Ti(O iPr)4 (0.3 equiv.), EtMgBr s (2M / Et2O, 3.0 equiv.), stirred for 1 hour, and then transferred to -5~0°C and stirred for 10-12 hours. After the reaction, ammonium chloride solution was added to quench, ethyl acetate was extracted, sodium chloride solution was washed, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Silica gel column chromatography was used for separation, and ethyl acetate and petroleum ether were used as gradient elution to obtain intermediate 10a.2 (white solid 0.6 g, 15%).
[0189] 1 H NMR (400MHz, CDCl3) δ3.31 (q, J=6.8Hz, 1H), 1.45 (s, 9H), 1.23 (d, J=6.9Hz, 3H), 0.82-0.72 (m, 3H), 0.54-0.51 (s, 1H).
[0190] Step 2: The intermediate 10a.2 (390 mg, 1.94 mmol) was added to 4 mL of dioxane, and 3 M dioxane hydrochloric acid solution (7.76 mmol) was added dropwise (3 M hydrochloric acid preparation: 1 mL of concentrated hydrochloric acid was added to 3 mL of dioxane) and stirred at room temperature for 20-22 h. After the reaction, the reaction solution was concentrated under reduced pressure. After acetonitrile was washed with water several times, a pink oil was obtained. 4 mL of acetonitrile was added and refrigerated for 10-12 h, filtered, washed with cold acetonitrile, and dried to obtain the intermediate 10a (white solid 180 mg, 91.8%).
[0191] 1 H NMR (400MHz, DMSO-d6) δ8.15 (br s, 3H), 5.81 (br s, 1H), 2.79-2.74 (m, 1H), 1.23 (d, J = 6.7Hz, 3H), 0.72-0.54 (m, 4H).
[0192] Synthesis of compound 10:
[0193]
[0194] Step 1: Compound 1b (206 mg, 0.5 mmol) was added to 3 mL of acetonitrile solution. DIEA (130 mg, 1 mmol) was added to another solution of compound 10a hydrochloride (138 mg, 1 mmol) in acetonitrile (2 mL) and mixed evenly. The mixture was added to the acetonitrile solution of compound 1b, and finally acetic acid (150 mg, 2.5 mmol) was added. The mixture was stirred at 70-80°C for 4-5 h. After the reaction was completed, sodium bicarbonate aqueous solution was added for washing, ethyl acetate was extracted, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 10c, which was directly used in the next step. MS m / z (ESI): 446.2 [M+1] + .
[0195] Step 2: Intermediate 10c was added to anhydrous THF, LiBr (4.0 equiv.) was added, and the reaction was stirred at 70-80°C for 6-8h. After the reaction was completed, 0.5M sulfuric acid solution was added to quench, ethyl acetate was added to extract, sodium bicarbonate solution was washed, and anhydrous sodium sulfate was dried and concentrated to obtain a mixture. Silica gel column chromatography was used for separation and dichloromethane / methanol gradient elution to purify compound 10 (off-white solid, 142 mg, two-step yield 66%). MS m / z (ESI): 432.2 [M+1] + .
[0196] 1 H NMR(400MHz,CDCl3)δ11.47(br s,1H),10.31(s,1H),8.36(s,1H),7.38-7.32(m,1H),6.83-6.78(m,2H),5.41-5.39(m,1H),4.68-4.56(m,1H),4.45(dd,J=1 2.3, 3.0Hz, 1H), 4.35 (q, J = 6.1Hz, 1H), 3.98 (t, J = 11.2Hz, 1H), 1.34 (d, J = 6.2Hz, 3H), 1.25-1.10 (m, 1H), 0.94-0.76 (m, 3H).
[0197] Embodiment 11
[0198] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: It was named (3'R,11a'S)-N-(2,4-difluorophenyl)-6'-hydroxy-3'-methyl-5',7'-dioxo-55',7',11',11a'-tetrahydro-3'H-spiro[cyclopentane-1,2'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide.
[0199] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0200] Preparation of intermediate 11a:
[0201]
[0202] Step 1: Referring to the operating conditions of 7a.3, intermediate 11a.1 was added to the freshly prepared Grignard reaction solution 7a.2 to prepare intermediate 11a.2 (light yellow oil 3.91 g, 50%).
[0203] 1H NMR (400MHz, CDCl3) δ7.35-7.27(m,8H),7.26-7.21(m,2H),4.35(s,1H),3.89(d,J=13.5Hz,2H),3.34(d,J=13.5Hz,2H), 2.92(q,J=7.0Hz,1H),1.90-1.78(m,1H),1.78-1.68(m,1H),1.69-1.54(m,3H),1.52-1.38(m,3H),1.09(d,J=7.0Hz,3H). 13 C NMR (100MHz, CDCl3) δ139.53,129.09,128.55,127.30,82.63,59.33,55.09,38.98,35.53,24.89,23.12,7.13.
[0204] Step 2: Referring to the Bn removal operation conditions of 1a, an oily product 11a was prepared and used directly in the next step reaction.
[0205] Synthesis of compound 11:
[0206]
[0207] Step 1: Compound 1b (251 mg, 0.84 mmol), compound 7a (160 mg, 1.22 mmol) and acetic acid (220 mg, 3.66 mmol) were added to 3 mL of acetonitrile and stirred at 70-80°C for 16 h. After the reaction, sodium bicarbonate aqueous solution was added for washing, ethyl acetate was extracted, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 11c, which was directly used in the next step. MS m / z (ESI): 474.2 [M+1] + .
[0208] Step 2: Add intermediate 11c to anhydrous THF, add LiBr (4.0 equiv.), stir and react at 70-80°C for 6-8h, add 0.5M sulfuric acid solution to quench after the reaction, add 3-5mL water to stir to precipitate solid, filter, wash with THF / water = 1:1, and dry to obtain compound 11 (white solid, 230 mg, two-step yield 63.5%). MS m / z (ESI): 432.2 [M+1] + .
[0209] 1H NMR(400MHz,DMSO-d6)δ11.44(br s,1H),10.33(t,J=3.6Hz,1H),8.46(s,1H),7.43-7.37(m,1H),7.28-7.22(m,1H),7.09-7.04(m,1H),5.42(d,J=10.2,4.0Hz,1H),4.83(d ,J=12.2,4.0Hz,1H),4.59-4.50(m,2H),4.17(q,J=6.5Hz,1H),3.99(dd,J=11.6,10.44Hz,1H),1.79-1.59(m,8H),1.30(d,J=6.7Hz,3H).
[0210] Example 12
[0211] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below: Named as: (3'R,11a'S)-N-(2,4-difluorophenyl)-6'-hydroxy-3'-methyl-5',7'-dioxo-5',7',11',11a'-tetrahydro-3'H-spiro[cyclohexane-1,2'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide.
[0212] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0213] Preparation of intermediate 12a:
[0214]
[0215] Step 1: Referring to the operating conditions of 7a.3, intermediate 11a.1 was subjected to Grignard reaction to prepare intermediate 12a.1 (white solid, 2.03 g, 12%).
[0216] 1 H NMR (400MHz, CDCl3) δ7.34-7.29(m,7H),7.28-7.21(m,1H),3.89(d,J=13.7Hz,2H),3.71(s,1 H), 3.36 (d, J = 13.7Hz, 2H), 2.61 (q, J = 7.1Hz, 1H), 1.73-1.18 (m, 10H), 1.09 (d, J = 7.1Hz, 3H). 13C NMR (100MHz, CDCl3) δ139.62,129.10,128.53,127.28,72.56,62.38,56.18,36.32,33.35,26.05,22.42,21.96,7.50.
[0217] Step 2: Referring to the Bn removal operation conditions of 1a, an oily product 12a was prepared and used directly in the next step reaction.
[0218] Synthesis of compound 12:
[0219]
[0220] Step 1: Compound 1b (231 mg, 0.56 mmol), compound 12a (200 mg, 1.4 mmol) and acetic acid (202 mg, 3.36 mmol) were added to 3 mL of acetonitrile and stirred at 70-80°C for 4-5 h. After the reaction, sodium bicarbonate aqueous solution was added for washing, ethyl acetate was extracted, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain intermediate 11a, which was directly used in the next step. MS m / z (ESI): 488.2 [M+1] + .
[0221] Step 2: Intermediate 11c was added to anhydrous THF, LiBr (4.0 equiv.) was added, and the reaction was stirred at 70-80°C for 10-12h. After the reaction was completed, 0.5M sulfuric acid solution was added to quench, ethyl acetate was added to extract, sodium bicarbonate solution was washed, anhydrous sodium sulfate was dried, and the mixture was filtered and concentrated to obtain a mixture. Methyl tert-butyl ether was added and stirred for crystallization for 2-4h, filtered, washed with methyl tert-butyl ether, and dried to obtain compound 12 (off-white solid, 180 mg, two-step yield 67.9%). MS m / z (ESI): 474.2 [M+1] + .
[0222] 1 H NMR(400MHz, CDCl3)δ11.55(br s,1H),10.33(t,J=5.7Hz,1H),8.35(s,1H),7.39-7.32(m,1H),6.84-6.77 (m,2H),5.40(dd,J=10.1,4.0Hz,1H),4.65(dd,J=16.0,6.2Hz,1H),4.61(d d,J=16.2,6.2Hz,1H),4.42(dd,J=12.4,4.2Hz,1H),4.13(q,J=6.7Hz,1H) ,3.87(dd,J=12.3,10.3Hz,1H),1.80-1.50(m,10H),1.36(d,J=6.8Hz,3H).
[0223] Embodiment 13
[0224] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below:
[0225] (2,4-difluorophenyl)-7'-hydroxy-6',8'-dioxo-2',3',6',8',12',12a'-hexahydrospiro[cyclopropane-1,4'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide (Compound 13);
[0227] (S)-N-(2,4-difluorophenyl)-7'-hydroxy-6',8'-dioxo-2',3',6',8',12',12a'-hexahydrospiro[cyclopropane-1,4'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide (Compound 14);
[0228] (R)-N-(2,4-Difluorophenyl)-7'-hydroxy-6',8'-dioxo-2',3',6',8',12',12a'-hexahydrospiro[cyclopropane-1,4'-pyrido[1',2':4,5]pyrazine[2,1-b][1,3]oxazine]-9'-carboxamide (Compound 15).
[0229] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0230] Preparation of intermediate 13a:
[0231]
[0232] Steps 1 and 2: Referring to the synthesis route of Journal of Medicinal Chemistry, 2016, 59, 8, 3732-3749, 2-cyanoethanol was used as the raw material, and the hydroxyl group was protected by TBSCl and then the amino alcohol was protected by kulinovich cyclopropane.
[0233] 1 H NMR (DMSO-d6) δ3.78 (t, J = 6.8 Hz, 1H), 1.65 (br s, 2H), 1.53 (t, J = 6.9 Hz, 2H), 0.83 (s, 9H), 0.37-0.30 (m, 3H), 0.04 (s, 6H).
[0234] Step 3: After deprotection of TBS with acetic acid, a reddish brown oil 13a was obtained, which was used directly in the next reaction.
[0235] Synthesis of compounds 13, 14 and 15:
[0236]
[0237] Step 1: Compound 1b (412 mg, 1 mmol), compound 13a (202 mg, 2 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and stirred at 70-80°C for 14-16 h. After the reaction, sodium bicarbonate aqueous solution was added for washing, ethyl acetate was extracted, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 13c, which was directly used in the next step. MS m / z (ESI): 446.1 [M+1] + .
[0238] Step 2: Add intermediate 13c to anhydrous THF, add LiBr (4.0 equiv.), stir and react at 70-80°C for 4-6 hours, add 0.5M sulfuric acid solution to quench after the reaction, add water to stir and crystallize for 1-3 hours, filter, and wash the solid with THF: water = 1:1 to obtain compound 13 (off-white solid, 177 mg, two-step yield 41%). MS m / z (ESI): 432.2 [M+1] + .
[0239] 1 H NMR(400MHz,DMSO-d6)δ12.53(br s,1H),10.41(t,J=5.8Hz,1H),8.57(s,1H),7.48-7.42(m,1H),7.33-7.27(m,1H),7.15-7.10(m,1H) ,5.38-5.34(d,1H),4.74(dd,J=14.7,1.2Hz,1H),4.63(dd,J=15.2,6.2Hz,1H),4.57(dd,J=15.0,5.7 Hz,1H),4.43(dd,J=14.4,2.9Hz,1H),4.15(dd,J=11.1,4.8Hz,1H),4.07(td,J=11.8,2.3Hz,1H),2. 33(td,J=12.4,5.2,1H),1.52-1.47(m,1H),1.18-1.08(m,2H),0.88-0.82(m,1H),0.77-0.72(m,1H).
[0240] Preparation of chiral compounds 14 and 15:
[0241] The mixture 13 (50 mg) was separated by SFC separation method (preparative column: ChiralPak AD, 250×30 mm ID, 10 μm; mobile phase: A phase CO2 / B phase isopropanol, gradient: B 25%; flow rate: 70 ml / min; column pressure: 100 bar; column temperature 38°C, wavelength 220 nm) to obtain compound 14 (retention time: 1.21 min), MS m / z (ESI): 432.1 [M+1] + ,Compound 15 (retention time: 1.46min), m / z (ESI): 432.1 [M+1] + .
[0242] Chiral HPLC purity method (preparative column: ChiralPak AD, 150×4.6 mm ID, 3 μm; mobile phase: A phase CO2 / B phase isopropanol (0.05% DEA), gradient: B 40%; flow rate: 2.5 ml / min; column pressure: 100 bar; column temperature 35° C., wavelength 220 nm).
[0243] Embodiment 14
[0244] The embodiment of the present invention provides a polycyclic aminoformyl pyridone derivative, the structural formula of which is shown below:
[0245] The naming is as follows:
[0246] N-(2,4-difluorophenyl)-6'-hydroxy-5',7'-dioxo-5',7',11',11a'-tetrahydro-2'H-spiro[cyclopropane-1,3'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide (Compound 16);
[0247] (S)-N-(2,4-difluorophenyl)-6'-hydroxy-5',7'-dioxo-5',7',11',11a'-tetrahydro-2'H-spiro[cyclopropane-1,3'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide (Compound 17);
[0248] (R)-N-(2,4-difluorophenyl)-6'-hydroxy-5',7'-dioxo-5',7',11',11a'-tetrahydro-2'H-spiro[cyclopropane-1,3'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide (Compound 18).
[0249] The present invention provides a method for preparing the above-mentioned polycyclic aminoformyl pyridone derivative, comprising:
[0250] Synthesis of compounds 16, 17 and 18:
[0251]
[0252] Step 1: Compound 1b (618 mg, 1.5 mmol) was added to 5 mL of acetonitrile solution. DIEA (387 mg, 3 mmol) was added to another solution of compound 16a hydrochloride (371 mg, 3 mmol) in acetonitrile (1 mL) and mixed evenly. The mixture was added to the acetonitrile solution of compound 1b, and finally acetic acid (540 mg, 9 mmol) was added. The mixture was stirred at 70-80°C for 20-24 h. After the reaction was completed, sodium bicarbonate aqueous solution was added for washing, ethyl acetate was extracted, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 16c, which was directly used in the next step. MS m / z (ESI): 432.2 [M+1] + .
[0253] Step 2: Intermediate 16c was added to anhydrous THF, LiBr (4.0 equiv.) was added, and the mixture was stirred at 70-80°C for 6-8h. After the reaction, 0.5M sulfuric acid solution was added to quench the mixture, and the mixture was stirred for 2-4h to precipitate a solid, which was filtered, washed with THF / water = 1:1, and dried to obtain compound 10 (off-white solid, 230 mg, two-step yield 36.7%). MS m / z (ESI): 418.2 [M+1] + .
[0254] 1 H NMR(400MHz, CDCl3)δ11.70(br s,1H),10.25(s,1H),8.27(s,1H),7.31-7.25(m,1H),6.77-6.71(m,2H),5.32(dd,J=10.1,3.6Hz,1H),4.56(d,J=5.8Hz,2H),4 .41(dd,J=12.2,3.5Hz,1H),4.13(d,J=8.6Hz,1H),4.06-3.95(m,2H),2.19-2.11(m,1H),2.02-1.94(m,1H),0.83-0.73(m,2H).
[0255] Preparation of chiral compounds 17 and 18:
[0256] The mixture 16 (100 mg) was separated by SFC (preparative column: ChiralPak AD, 250×30 mm ID, 10 μm; mobile phase: A phase CO2 / B phase isopropanol (0.1% ammonia water), gradient: B 40%; flow rate: 80 ml / min; column pressure: 100 bar; column temperature 38°C, wavelength 220 nm).
[0257] Compound 17 (51 mg, retention time 2.79 min) was prepared respectively, MS m / z (ESI): 418.1 [M+1] + ,Compound 18 (39 mg, retention time 5.84 min), MS m / z (ESI): 418.1 [M+1] + .
[0258] Chiral HPLC purity method (preparative column: ChiralPak AD, 150×4.6 mm ID, 3 μm; mobile phase: A phase CO2 / B phase isopropanol (0.05% DEA), gradient: B 40%; flow rate: 2.5 ml / min; column pressure: 100 bar; column temperature 35° C., wavelength 220 nm).
[0259] Example 15: Compound Evaluation
[0260] The properties of the compounds of the present invention were verified by compound activity test, integrase inhibition activity test, oil-water partition coefficient of the compound, compound PK test (mice), and compound PK test (crab-eating monkey).
[0261] The structure of the control drug involved in the above test is as follows:
[0262]
[0263] 1. Activity Test
[0264] 1. Experimental Materials
[0265] ——Virus: The HIV-1 pseudovirus used in this experiment is a replication-defective virus constructed by WuXi AppTec.
[0266] ——The cell line HEK 293T cells were purchased from ATCC, catalog number CRL-11268. The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% double antibody.
[0267] ——Reagents
[0268] Reagent name supplier Part Number Fetal bovine serum (FBS) Excell Bio FSP500 Double antibody solution (PS) Hyclone SV30010 DMEM Gibco 11960-051 Luciferase reporter gene assay reagent Britelite plus kit PerkinElmer 6066769 Cell viability detection reagent kit CellTiter Glo Promega G7553
[0269] ——Main instruments
[0270] Instrument Name Supplier / Model model Multi-label microplate reader Envision PerkinElmer Envision2104 ELISA reader Bio Tek Synergy
[0271] 2. Experimental Methods
[0272] HIV-1 pseudovirus infection experimental method
[0273] Virus strain cell Processing time (days) / experiment Control Compound HIV-1 pseudovirus HEK 293T 3 / Luc RAL
[0274] (1) Cell plating:
[0275] On the first day, HEK 293T cells were seeded into 96-well test plates at a density of 55,000 cells per well, 100 μL per well, and cultured overnight in a 5% CO 2 , 37° C. incubator.
[0276] (2) Compound treatment and viral infection:
[0277] On the second day, the test compound (the compound provided in the example of the present invention) and the control compound were diluted 4-fold with cell culture medium, with a total of 8 concentration points. 50 μL of the diluted compound was added to each well, and duplicate wells were prepared.
[0278] HIV-1 pseudovirus was then diluted to 100 TCID50 / 50 μL with cell culture medium, and 50 μL of the diluted virus was added to each well.
[0279] Cell controls (cells, no compound treatment or virus infection) and virus controls (cells infected with virus, no compound treatment) were set up. The final starting test concentration of the test compound and the control compound was 1000 nM (Table 1), and the virus infection amount was 100 TCID50 per well. The total volume of the cell culture medium was 200 μL per well, and the final concentration of DMSO in the culture medium was 0.5%.
[0280] The cells were cultured in a 5% CO2, 37°C incubator for 3 days.
[0281] (3) Luciferase activity detection:
[0282] On the fifth day, 100 μL of cell supernatant was removed from each well of the antiviral activity test plate, and 100 μL of 2× luciferase reporter gene detection reagent Britelite plus was added in a dark place. Envision was used to detect the luciferase activity of each well in the test plate. The data were used for the antiviral activity analysis of the samples.
[0283] (4) Cytotoxicity assay:
[0284] On the fifth day, 100 μL of cell supernatant was removed from each well of the cytotoxicity test plate, and 100 μL of cell viability test reagent CellTiter Glo was added in a dark place. The cell viability of each well was detected using a BioTek microplate reader, and the data were used for sample cytotoxicity analysis.
[0285] (5) Data processing:
[0286] The dose-effect curve was drawn using GraphPad Prism software. The calculation formulas for antiviral activity (% Inhibition) and cell viability (% cell viability) are as follows:
[0287] Antiviral activity (%) = (test well reading - virus control average) / (cell control average - virus control average) × 100; Cell viability (%) = (test well reading - medium control average) / (cell control average - medium control average) × 100;
[0288] EC 50 and CC 50 GraphPad Prism (version 5) software was used to perform nonlinear fitting analysis on the inhibitory activity of the compounds and the cell viability, and the fitting method was "log (inhibitor) vs. response--Variable slope".
[0289] 3. HIV-1 pseudovirus experiments were used to determine the in vitro antiviral activity and cytotoxicity of the test compounds on HEK 293T cells. The experimental results are shown in the table below.
[0290] Table 1. Antiviral activity results of the compounds
[0291]
[0292]
[0293] Note: EC 50 : The concentration of compound that protects 50% of HIV-infected MT-4 cells from cytopathic effect; CC 50 : The concentration of the target compound that causes 50% of cells not infected with HIV to become pathological.
[0294] The results showed that the control compounds RAL, DTG and the tested compounds all had antiviral activity against HIV-1 pseudovirus, and the compounds did not show significant cytotoxicity on HEK 293T cells. 50 The value was greater than the highest tested concentration.
[0295] 2. Integrase activity test
[0296] This experiment uses a non-radioactive assay, the Integrase Assay Kit, to quantitatively measure integrase activity. HIV-1 integrase removes two bases from the 3' end of the donor double-stranded DNA (DSDNA) and catalyzes the integration of the cleaved DS NDA into the double-stranded target substrate DNA (TSDNA) containing a 3' end modification. The HRP-labeled antibody is specific for the 3' end modification, and the absorbance value is read at 450nm to quantify the integrase activity.
[0297] 1. Reagents and consumables:
[0298] HIV-1Integrase Assay Kit#EZ-1700
[0299] 14.5Mβ-mercaptoethanol (BME), metal bath, incubator, 96-well culture plate (NEST)
[0300] Benchtop ELISA reader ( iD5), DMSO;
[0301] Test compounds: Compound 1, Dolutegravir (DTG), Bictegravir (BIC)
[0302] 2. Experimental steps
[0303] (1) Reagent preparation:
[0304] Prepare each component according to the kit instructions; prepare the test sample, prepare 5mM DMSO solution of the test sample for use, prepare the working solution according to the starting and ending concentrations determined when the method was established, and dilute it 4 times to 10 concentrations.
[0305] (2) Methodology establishment: The EZ-1700 kit was used to establish the methodology;
[0306] ① Use Azide to conduct data reproducibility experiments and determine the antibody incubation time;
[0307] ② Explore the detection concentrations of compound 1, DTG and BIC;
[0308] (3) Test sample testing
[0309] ① Prepare the test sample working solution according to the starting concentration determined during the methodology establishment process;
[0310] ② Prepare the reagents according to the method provided in the kit;
[0311] ③DSDNA coating - blocking - adding integrase solution - adding test sample - adding TS DNA - adding HRP antibody - adding TMB peroxidase substrate - TMB termination reaction - detecting the absorbance at 450nm.
[0312] The IC curve was fitted using the software Graphpad Prism 8.0 and the calculation formula Log(inhibitor) vs.response-variable slope. 50 .
[0313] The IC values of the compounds of the present invention determined by the above test are 50 See the table below for values.
[0314] Table 2. Integrase inhibitory activity results of compounds
[0315] Test product <![CDATA[IC 50 (nM)]]> Compound 1 9.19 DTG 13.60 BIC 21.24
[0316] Conclusion: The compounds of the present invention can inhibit HIV integrase activity, and have better inhibitory effects on integrase activity than dolutegravir (DTG) and bictegravir (BIC).
[0317] 3. Oil-water partition coefficient of compounds
[0318] Oil-water partition coefficient of a compound
[0319] a) Add 1 mL of n-octanol and 1 mL of pH 7.4 phosphate buffer into a 5 mL glass bottle.
[0320] b) The compound was added to DMSO solution to prepare a compound stock solution with a process concentration of 10 mM, and then 20 μL of the compound stock solution was added to a mixture of n-octanol and phosphate buffer.
[0321] c) Shake at room temperature at a rate of 300 / min for 1 hour.
[0322] d) Let the solution stand for 30 minutes, and after the solution is completely separated, take out the upper and lower layer solutions respectively, put them into a 96-well deep-well plate, and perform LC-MS / MS sampling detection.
[0323] e) Serial dilutions of 1-octanol and aqueous solutions were performed using DMSO to obtain final samples for LC-MS / MS analysis. Three serial dilutions were performed for each 1-octanol phase, covering a 2500-fold concentration range. Each final aqueous phase was serially diluted twice, covering a 100-fold concentration range. The MS peak areas of these solutions were used to generate log(peak area) based on a log(relative concentration) calibration line.
[0324] LogD(pH7.4)=LOG(Coct / Caq)
[0325] Coct = sample concentration in n-octanol
[0326] Caq = sample concentration in pH 7.4 phosphate buffer
[0327] Table 3. Oil-water partition coefficients of compounds
[0328]
[0329]
[0330] Note:
[0331] 1<LogD7.4<3 is an ideal range. Since there is a good balance between solubility and passive diffusion permeation, such compounds usually have good small intestinal absorption.
[0332] 3<LogD7.4<5 Due to poor solubility, this type of compound has good permeability but low absorption;
[0333] The low solubility of LogD7.4>5 results in poor absorption and bioavailability of compounds in this range.
[0334] Conclusion: At pH 7.4, the log D values of DTG, compound 6, compound 1, and compound 2 were 1.6, 2.0, 2.2, and 2.5, respectively, indicating that these compounds are well absorbed in the small intestine. In the process of small intestinal absorption, the higher the log D value, the better the lipid solubility and cell permeability. Therefore, the cell permeability of the above compounds is ranked from high to low as compound 2>compound 1>compound 6>DTG.
[0335] 4. Compound PK test (mice)
[0336] 1. Summary
[0337] ICR mice were used as test animals, and the drug concentrations in plasma at different times after the mice were given compounds (Compound 1, Compound 2, Compound 6, Compound 10) and positive control (DTG) by oral gavage (PO) and intravenous injection (IV) were determined by LC-MSMS. The pharmacokinetic behavior of the compound in mice was studied and its pharmacokinetic characteristics were evaluated.
[0338] 2. Experimental drugs
[0339] Compound 1, compound 2, compound 6, compound 10 and positive control example dolutegravir (DTG).
[0340] 3. Experimental Animals
[0341] SPF grade ICR male mice, 10 weeks old, weighing about 32g, 6 mice in each group, for a total of 48 mice.
[0342] 4. Test recipe
[0343] Oral administration group (PO): 5% DMSO / 10% Solutol / 85% (20% Captisol in water);
[0344] Intravenous injection group (IV): 5% DMSO / 10% Solutol / 85% (20% Captisol in water).
[0345] 5. Drug administration
[0346] The mice were not fed before 5 pm the day before administration and fasted overnight, but were not deprived of water. The IV group was given 2 mg / kg, and the PO group was given 10 mg / kg. Eating was resumed 2 hours after administration.
[0347] 6. Sampling
[0348] Mice were gavaged and 20 μL of blood was collected from the saphenous vein of the lower leg before and 0.25, 0.5, 1, 2, 4, 8, and 24 hours after administration, respectively, and placed in EDTA-K2 anticoagulant blood collection tubes. The blood samples were placed on ice until centrifuged to obtain plasma samples. The plasma samples were centrifuged at 4°C (3500 rpm, 10 min), and after separation, the samples were transferred to EP tubes and stored at -80°C until detection.
[0349] Mice were intravenously injected with drugs, and 20 μL of blood was collected from the saphenous vein of the lower leg before and 0.0833, 0.25, 0.5, 1, 2, 4, 8, and 24 hours after administration, respectively. The blood samples were placed in EDTA-K2 anticoagulant blood collection tubes, and the blood samples were placed on ice until centrifuged to obtain plasma samples. The plasma samples were centrifuged at 4°C (3500rpm, 10min), and after separation, the samples were transferred to EP tubes and stored at -80°C until detection.
[0350] 7. Detection
[0351] Determine the content of the test compound in mouse plasma after oral administration of different concentrations of the drug: take 10 μL of mouse plasma at each time after administration, add 100 μL of methanol containing internal standard (100 ng / mL), vortex mix for 1 min, centrifuge at 4°C (12000 rpm, 5 min), and take 1 μL of the supernatant of the plasma sample for LC-MS / MS analysis.
[0352] 8. Pharmacokinetic parameter results
[0353] Table 4. Mouse PK results of compounds
[0354]
[0355] 9. Summary
[0356] The results of the mouse PK test showed that compounds 1, 2, 6, and 10 had good bioavailability. Among them, the bioavailability and half-life data of compound 1 were better than those of the positive control DTG.
[0357] 5. Compound PK test (cynomolgus monkey)
[0358] 1. Summary
[0359] Using cynomolgus monkeys as test animals, the drug concentration in plasma at different times after oral administration (PO) of compound 1 was determined by LC-MS / MS method. The pharmacokinetic behavior of the disclosed compound in cynomolgus monkeys was studied and its pharmacokinetic characteristics were evaluated.
[0360] 2. Experimental drugs
[0361] Compound 1.
[0362] 3. Experimental Animals
[0363] Cynomolgus monkeys (Macaca fascicularis), normal grade, male, about 2.5 to 4 years old, body weight range 2 to 5 kg, 3 per group.
[0364] 4. Test recipe
[0365] Compound 1 and a solid substrate (hydroxypropylmethylcellulose acetate succinate) are dissolved in an organic solvent, and the solvent is removed by heating and evaporation, or the solution is removed by a spray drying device to obtain Compound 1 attached to the solid substrate.
[0366] Compound 1 attached to a solid substrate obtained according to the above steps is slowly added to a suitable container containing about 80% of the final volume of the solvent while stirring. Stir until visually uniform, and if necessary, ultrasonically treat the preparation. Add the solvent to the desired concentration. The obtained preparation is continuously stirred until a uniform preparation is obtained by visual inspection, and if necessary, the preparation is ultrasonically treated. A dosing concentration of 20 mg / mL of API concentration is prepared, and the preparation method of the above solvent is as follows: add about 30% of the total volume of purified water to an appropriate container and heat to about 80°C to 90°C, slowly add the required volume of Tween 80 to the above container, and stir until visually uniform. Add purified water to the final volume. Stir until a visually uniform solution is obtained.
[0367] 5. Drug administration
[0368] The cynomolgus monkeys were fasted overnight and had free access to water. The PO group was given 100 mg / kg and resumed eating 2 hours after administration.
[0369] 6. Sampling
[0370] The cynomolgus monkeys were gavaged and 20 μL of blood was collected from the hind limb vein before and 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, and 96 hours after administration. The blood samples were placed in EDTA-K2 anticoagulant blood collection tubes. The blood samples were placed on ice until centrifuged to obtain plasma samples. The plasma samples were centrifuged at 4°C (3500 rpm, 10 min). After separation, the samples were transferred to EP tubes and stored at -80°C until detection.
[0371] 7. Detection
[0372] Determine the content of the test compound in the plasma of crab-eating monkeys after oral administration of different concentrations of the drug: take 10 μL of monkey plasma at each time after administration, add 100 μL of methanol containing internal standard (100 ng / mL), vortex mix for 1 min, centrifuge at 4°C (12000 rpm, 5 min), and take 1 μL of the supernatant of the plasma sample for LC-MS / MS analysis.
[0373] 8. Pharmacokinetic parameter results
[0374] Table 5. PK results of compounds in cynomolgus monkeys
[0375]
[0376] 9. Summary
[0377] The test results showed that the T 1 / 2 The half-life of the preferred compound 1 of the present invention is relatively long, which can reduce the frequency of medication for AIDS patients, overcome the inconvenience of multiple medications, and better meet the requirements of medical medication.
[0378] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A polycyclic aminoformyl pyridone derivative, or a pharmaceutically acceptable salt thereof, characterized in that: The polycyclic aminoformyl pyridone derivative is a compound represented by the following structural formula:
2. A method for preparing the polycyclic carbamoyl pyridone derivative according to claim 1, characterized in that: The steps include: Wherein, compound 1b is used as the starting material, and is subjected to intramolecular ring closure with compound 16a under acid catalysis to obtain intermediate 16c; and Intermediate 16c is subjected to demethylation reaction to obtain compound 16.
3. The preparation method according to claim 2, characterized in that: The conditions for preparing intermediate 16c include: the molar ratio of compound 1b to compound 16a is 1:1-1:5, the temperature is 30-100°C; the time is 5 minutes-16 hours; The conditions for preparing compound 16 include: temperature of 30-100° C.; time of 5 minutes to 16 hours.
4. A pharmaceutical composition, characterized in that The invention comprises the polycyclic aminoformyl pyridone derivative according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition according to claim 4, characterized in that The pharmaceutically acceptable carrier is selected from water for injection, lyophilized powder excipients or oral preparation excipients.
6. Use of the polycyclic aminoformyl pyridone derivative according to claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 4 or 5 in the preparation of a medicament for preventing and / or treating diseases mediated by HIV infection.
